Zenlabs Ethica Ltd
₹ 26.5
-5.69%
05 Oct
4:01 p.m.
About
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products.[1]
Key Points
- Market Cap ₹ 17.2 Cr.
- Current Price ₹ 26.5
- High / Low ₹ 40.0 / 16.5
- Stock P/E
- Book Value ₹ 13.1
- Dividend Yield 0.00 %
- ROCE 5.07 %
- ROE 0.21 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.70% over past five years.
- Company has a low return on equity of 2.39% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -6.16%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 15.09 | 78.73 | 69.85 | 65.37 | 58.50 | 56.64 | 69.09 | 66.89 | 58.56 | 51.42 | 46.92 | 49.62 | |
| 0.05 | 14.89 | 77.28 | 68.00 | 63.28 | 59.20 | 54.89 | 66.70 | 63.98 | 56.15 | 48.84 | 45.13 | 48.67 | |
| Operating Profit | -0.05 | 0.20 | 1.45 | 1.85 | 2.09 | -0.70 | 1.75 | 2.39 | 2.91 | 2.41 | 2.58 | 1.79 | 0.95 |
| OPM % | 1.33% | 1.84% | 2.65% | 3.20% | -1.20% | 3.09% | 3.46% | 4.35% | 4.12% | 5.02% | 3.82% | 1.91% | |
| 0.00 | -0.03 | 0.08 | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | -0.45 | 0.30 | 0.04 | -1.90 | -1.90 | |
| Interest | 0.00 | 0.02 | 0.10 | 0.09 | 0.07 | 0.23 | 0.29 | 0.37 | 0.53 | 0.83 | 0.93 | 0.81 | 0.76 |
| Depreciation | 0.01 | 0.06 | 0.20 | 0.20 | 0.23 | 0.29 | 0.71 | 0.89 | 1.25 | 1.29 | 1.26 | 0.89 | 0.72 |
| Profit before tax | -0.06 | 0.09 | 1.23 | 1.66 | 1.89 | -1.17 | 0.86 | 1.22 | 0.68 | 0.59 | 0.43 | -1.81 | -2.43 |
| Tax % | 16.67% | -88.89% | 21.95% | 29.52% | 32.80% | -36.75% | 10.47% | 36.07% | 26.47% | 27.12% | 37.21% | 6.63% | |
| -0.07 | 0.17 | 0.95 | 1.16 | 1.26 | -0.73 | 0.77 | 0.78 | 0.49 | 0.42 | 0.27 | -1.94 | -2.54 | |
| EPS in Rs | -0.18 | 0.26 | 1.46 | 1.78 | 1.94 | -1.12 | 1.18 | 1.20 | 0.75 | 0.65 | 0.41 | -2.98 | -3.91 |
| Dividend Payout % | 0.00% | 0.00% | 16.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33.21% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -4% |
| 3 Years: | -11% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -23% |
| 5 Years: | -52% |
| 3 Years: | -72% |
| TTM: | -277% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -3% |
| 3 Years: | -8% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.62 | 6.20 | 6.20 | 6.20 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves | -1.65 | -1.41 | -0.41 | 0.81 | 1.77 | 0.90 | 2.05 | 2.82 | 3.19 | 3.61 | 3.92 | 2.00 |
| 0.00 | 1.09 | 0.96 | 0.85 | 0.60 | 0.73 | 2.60 | 3.90 | 5.85 | 14.86 | 12.71 | 10.98 | |
| 1.77 | 24.49 | 26.62 | 21.96 | 26.01 | 25.85 | 21.04 | 24.66 | 27.95 | 15.28 | 17.48 | 17.71 | |
| Total Liabilities | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 37.20 |
| 0.06 | 1.68 | 1.50 | 1.33 | 1.36 | 1.12 | 3.51 | 3.53 | 5.03 | 3.70 | 2.29 | 1.87 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 1.25 | 0.95 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.00 |
| 3.68 | 27.44 | 30.92 | 27.79 | 32.83 | 32.17 | 27.99 | 33.66 | 37.77 | 35.86 | 37.63 | 35.33 | |
| Total Assets | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 37.20 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.92 | -1.06 | 0.36 | 0.80 | 0.45 | -8.41 | -0.38 | 1.52 | -9.06 | 3.83 | 4.06 | |
| 0.00 | -1.69 | -0.02 | -0.03 | -0.22 | 0.01 | 0.15 | 0.00 | -1.47 | 0.11 | 0.14 | 0.00 | |
| 0.00 | 3.23 | -0.27 | -0.23 | -0.14 | -0.03 | -0.52 | 0.31 | 0.06 | 8.24 | -3.08 | -2.95 | |
| Net Cash Flow | 0.02 | 2.47 | -1.35 | 0.09 | 0.44 | 0.43 | -8.78 | -0.07 | 0.11 | -0.71 | 0.88 | 1.11 |
| Free Cash Flow | 0.02 | -0.77 | -1.08 | 0.33 | 0.49 | 0.40 | -8.35 | -0.41 | -0.03 | -9.08 | 3.96 | 4.06 |
| CFO/OP | -40% | 460% | -73% | 19% | 38% | -64% | -475% | -11% | 62% | -371% | 157% | 234% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 398.14 | 107.65 | 126.40 | 139.37 | 138.76 | 121.67 | 109.57 | 118.41 | 129.21 | 138.70 | 122.13 | |
| Inventory Days | 249.62 | 34.42 | 11.12 | 31.23 | 33.95 | 40.46 | 56.05 | 77.85 | 100.05 | 128.43 | 161.14 | |
| Days Payable | 665.46 | 136.41 | 125.88 | 161.27 | 165.31 | 150.28 | 141.30 | 174.04 | 101.21 | 140.00 | 165.22 | |
| Cash Conversion Cycle | -17.70 | 5.66 | 11.64 | 9.33 | 7.40 | 11.85 | 24.32 | 22.21 | 128.04 | 127.13 | 118.05 | |
| Working Capital Days | 4.84 | 13.40 | 21.95 | 28.42 | 24.02 | 27.97 | 35.34 | 34.98 | 47.31 | 52.74 | 39.44 | |
| ROCE % | -2.99% | 9.94% | 21.06% | 23.96% | 24.13% | -11.05% | 12.02% | 13.04% | 12.44% | 7.01% | 5.69% | 5.07% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of permanent employees employees |
|
||||||||
| Number of therapeutic categories categories |
|||||||||
| Export revenue as % of total revenue % |
|||||||||
| Number of products in portfolio products |
|||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- AGM on 29 Sep 2026 reappointed N. Kumar Chabbra & Co. as statutory auditors for five years.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Members re-appointed N. Kumar Chabbra & Co. as statutory auditors for five years on 29 September 2026.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
- Members approved MOA object-clause alteration at 33rd AGM on 29 Sep 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 33rd AGM held on 29 Sep 2026; shareholders approved financials, reappointment, and object clause amendment.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2]
a) ZEL is a part of the Preet Remedies Group. It is a WHO–GMP certified contract manufacturing pharmaceutical firm which operates across manufacturing and distributing diversified pharmaceutical formulations under multiple divisions (Zenlabs, Coles Pharma, Mega Star), servicing both domestic and international markets including Southeast Asia.
b) The company does third party manufacturing for Preet Remedies Group which has 5 production units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, the minimum
order quantity offered is 2000 boxes
of drugs.
c) The company is also into private label manufacturing of different pharmaceutical products.